razoxane has been researched along with B16 Melanoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borgel, SD; Hollingshead, MG; Kaur, G; Kong, D; Melillo, G; Newton, DL; Rybak, SM; Sanovich, E; Sausville, EA | 1 |
| Barret, JM; Etiévant, C; Hill, BT; Kruczynski, A; van Hille, B | 1 |
| Hoshino, A; Inaba, M; Komatsu, T; Narita, T; Takase, M; Tsukagoshi, S; Yaguchi, S | 1 |
3 other study(ies) available for razoxane and B16 Melanoma
| Article | Year |
|---|---|
"Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Division; Cell Hypoxia; Cyclohexanes; Drug Design; Endothelial Growth Factors; Endothelium, Vascular; Female; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Razoxane; Sesquiterpenes; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2003 |
Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Diketopiperazines; DNA Damage; DNA Topoisomerases, Type II; DNA, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Etoposide; Female; Humans; Leukemia P388; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Naphthalenes; Neoplasm Transplantation; Piperazines; Pyrans; Razoxane; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2000 |
Antitumor activity of MST-16, a novel derivative of bis(2,6-dioxopiperazine), in murine tumor models.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Leukemia P388; Leukemia, Experimental; Melanoma, Experimental; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Piperazines; Razoxane; Structure-Activity Relationship; Tumor Cells, Cultured | 1990 |